Elanco Animal Health Incorporated (NYSE:ELAN) Given Consensus Recommendation of “Hold” by Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given an average recommendation of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $15.83.

ELAN has been the topic of a number of analyst reports. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday. Leerink Partners initiated coverage on shares of Elanco Animal Health in a report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective on the stock. Stifel Nicolaus cut their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Morgan Stanley cut their price objective on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday. Finally, Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a report on Monday, December 2nd.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $11.19 on Friday. The company has a fifty day simple moving average of $11.71 and a 200 day simple moving average of $13.03. Elanco Animal Health has a 12-month low of $10.20 and a 12-month high of $18.80. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a market cap of $5.53 billion, a P/E ratio of 27.96, a PEG ratio of 2.50 and a beta of 1.42.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business posted $0.08 EPS. The business’s revenue for the quarter was down 1.4% compared to the same quarter last year. Sell-side analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Hedge funds have recently made changes to their positions in the business. CoreCap Advisors LLC bought a new stake in shares of Elanco Animal Health during the 4th quarter worth $29,000. AM Squared Ltd bought a new stake in shares of Elanco Animal Health during the 3rd quarter worth $34,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health during the 3rd quarter worth $35,000. Farther Finance Advisors LLC raised its stake in shares of Elanco Animal Health by 158.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after purchasing an additional 2,044 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in shares of Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after purchasing an additional 1,601 shares during the period. 97.48% of the stock is currently owned by institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.